EWM
RUBY

Edge Wealth Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Edge Wealth Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$1.75K – 86
2022
Q4 		$1.75K Hold
10,000
– – ﹤0.01% 86
2022
Q3 		$4K Hold
10,000
– – ﹤0.01% 83
2022
Q2 		$9K Buy
+10,000
New +$16.8K ﹤0.01% 88

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Edge Wealth Management's RUBY Position: Q1 2023 in Review

Edge Wealth Management sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 10,000 shares — an estimated $1.75K sold.

Edge Wealth Management first reported a position in RUBY in Q2 2022 and held it in 3 quarters. The position peaked at $9K in Q2 2022. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Edge Wealth Management reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Edge Wealth Management sold 10,000 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $1.75K.
  • Edge Wealth Management first reported a position in Rubius Therapeutics, Inc in Q2 2022 and held it in 3 quarters.
  • Edge Wealth Management's Rubius Therapeutics, Inc position peaked at $9K in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Edge Wealth Management's 13F filing for Q1 2023, filed 18 Apr 2023.